We just thought we would post a current summary of the status of ErSO as we know it. It can be hard to separate the varied and sometimes conflicting information we receive from different sources over the internet and part of the reason for this group is to share what we know is accurate. See dot points below for the recent developments :
• Bayer has terminated the licensing deal with Systems Oncology and will no longer be developing ErSO
• Plans for ErSO to move to clinical trials are still moving forward, with Systems Oncology now in charge of the future planning
• We have very good reason to believe that the reason(s) the Bayer/Systems Oncology deal fell over were not related to the safety or efficacy of ErSO.
• The researchers at the University of Illinois are still working on developing ErSO to help it progress to trials
• We hope to have more information coming soon and possibly some more media coverage as we have had contact with a number of journalists and people heavily involved in the Biotech industry
Of course any further accurate info we get we will share as soon as we can. Along with everyone else we hope to hear the next steps for ErSO soon
Written by
Cureforever
To view profiles and participate in discussions please or .
Thanks for the update and for your faith in following up this project for all of us. It is good to know that the project has not been shelved. It gives us something to look forward to again after our hopes were dashed when Bayer terminated their licensing agreement.
Right and thanks for your honesty. How in the world can a pharma company transfer funds in the millions and then back out, we, not knowing the stipulations of the agreement? Is this really profit over patients? It was proven to kill cancer cells in a manner of days.........OUR days are numbered. Why don't the care? Something is not right here. Perhaps we can get an answer from Media Contact
Systems Oncology
Katy Marhenke
info@systemsoncology.com
People are dying from this disease on a daily basis, whom do not need to. Media SHOULD be all over this and getting interviews and asking questions, WHAT THE HECK IS GOING ON HERE?
Hi. You may write to her. I am going through very difficult time now. I have another gyno cancer in addition to mbc. I am expecting a surgery. I still hope that ErSo will come around and cure us. Systems oncology is working on it. They modified the molecule. It’s a good idea to contact Katy. We still have ErSo group on Facebook but the admins are not very active. Members contacted researchers on their own. The latest answer is posted there.
Hi I am expecting a surgery today. Unfortunately I was diagnosed with endometrial cancer in addition of having mbc. I have no strength to post here but I will share the responses from the researchers and Systems Oncology. You can post them to this board if you would like to. April
Dr Hergenrother
Here is the update from Professor Paul J. Hergenrother.
Hi Olga,
Thanks for reaching out. As you know I am not part of the day-to-day operations at Systems Oncology, where they are working to push this technology toward human clinical trials. But, from everything I know things are moving forward apace, with focus on the detailed and lengthy tolerability studies required by the FDA. I would think that toward the end of the summer Systems Oncology might have a more concrete timeline for advancement, so I would suggest that you reach out to them at that point.
Thanks so much for you advocacy and feel free to check back periodically, and best regards,
Kenneth L. Rinehart Endowed Chair in Natural Products Chemistry
Here's the latest update/response from Madeline Sell at SO yo the FB admin
Dear Anja,
On behalf of Systems Oncology we offer our deepest condolences for the loss of Jeanine. Her advocacy on behalf of so many patients was inspirational. At this moment we do not have any updates to offer. However, we continue to work diligently with the goal of advancing our therapies as quick as possible. I would like to introduce you to Katy Marhenke. Katy has been with Systems Oncology from the very beginning and will be taking over as your point of contact as I transition to another company. Thank you again for being a representative and advocate for your community.
Best,
Madeline Sell
The responses I received in March
Dear Marina:
Excuse the delay in responding. Dealing with Covid in our lab.
The energy and resilience of the MBC community is inspiring. Although I am not a consultant to Systems Oncology we remain in close contact. Systems Oncology, our laboratory and that of Professor Hergenrother are all working with passion and energy to develop the information needed to move forward to a clinical trial as quickly as possible.
Most current cancer drugs moving toward a clinical trial are either related to an already approved cancer drug, or target the same protein or process in the cancer cell as an FDA approved drug. ErSO and ErSO family members are an entirely new type of cancer drug; this means there is a good deal to do in order to assemble the information for an FDA approved clinical trial.
While we all wish we could provide a specific timeline for clinical transition, it depends on ongoing work guided by Systems Oncology and in the research laboratories.
Moving ErSO or an ErSO family member forward to the clinic remains at the center of our work.
My Best to you and the entire MBC community
David
Professor David J. Shapiro, Eugene Howe Scholar
Department of Biochemistry and Cancer Center at Illinois
314D RAL, University of Illinois
600 S. Mathews Avenue
Urbana, IL 61801-3602 USA
email: djshapir@illinois.edu
Hi Marina,
Thanks so much for your note and for all your advocacy. Prof. Shapiro and I are acutely aware of the needs of MBC patients, which is why we have dedicated so much of our careers to this work – the courage of you and others living with MBC is truly inspiring to us!
Thanks also for forwarding the update from Madeline Sell, and actually, I do not view this as discouraging at all. I can tell you that Systems Oncology is doing everything they can to advance this to the clinic as fast as possible. I have been involved in the translation of 4 different anticancer compounds, so, I can tell you that when she makes those comments about the timeline, what it means is there are certain experiments that simply cannot be sped up. For example, for another anticancer compound of ours the FDA wanted data from an 84-day toxicology study – so, these experiments simply take time, often months. With these regulations the FDA tries to balance the acute needs of patients with ensuring safety for any new drug candidate.
I hope this helps; please know that Prof. Shapiro and I are doing all we can and we both remain very optimistic! Thanks for making contact and please feel free to reach out to me periodically and best regards,
Paul
Dear Marina,
Thank you for reaching out on behalf of so many patients. I am acting as the point of contact for questions regarding this program. I would like to reassure you that we are proceeding with urgency and spending considerable time and resources on advancing this program. We understand there is a great deal of need in the community and are actively working to fulfill that need. While we are proceeding as quickly as possible, the timeline for advancement is dictated not by us but by the results of scientific experiments. I apologize that we do not have more encouraging news at this moment. I will continue to keep your group updated with any relevent advancements.
We all hope that your surgery goes well. We also all thank you for taking the time to post this information on the day of your surgery. You are a trooper. Stay strong. For other reading these links and posts, I jut have one last thought. Did anyone, realize that what they stated they are trying to do, has actually already been tested? What is the delay? They real delay. If there is a cancer drug that can help so many people around the world, it is hard to fathom their reasoning. Fast track covid, great and done. Fast track a potential cure for millions of people with MBC? Hmmm..why not fast track ErSO too, the preclinical studies are already proven for goodness sakes. The safety and tolerance has already been studied in pre-trials. PLUS, it is shown to work in as little as 3 DAYS. I also find it interesting that other pharma's have not stepped up to the plate to take this on. 2 have backed out of deals, why? Perhaps causing a rif in the profits of all the other toxic, long term issues, that this drug does not have, hence losing billions in profits? One would think with all the drugs for each type of cancer, from so many different pharma's that one would stand out and not fail. This one does, why not go forward. When I research new drugs that are being "offered" as standard treatment or now, in a CT, I find it hard to first find the effectiveness of the drug and side effects. Firstly, it is all about profit and Q1,2,3 and 4 fiscal statements, nothing comes up first as THIS COMPANY HAS A DRUG THAT WILL PROLIFERATE CANCER IN 3 DAYS. The issues and long term issues are a crap shoot at that. Sorry to have ranted, but something just is not right with why this life saving drug is not in the media and should be and should have been since the finding and statement by Dr. Shapiro, life changing, hell yeah. Where is the media, where are the people that advocate for these drugs, what is the actual hold up? Will we ever know? Will we ever have hope? Thank you for your patience. I feel a bit better now.
Thank you for your wishes. I am home already. Pain on and off I agree with you. We tried to approach media but only one reporter ASh Har wrote about ErSo but the old version. They modified it. Now it’s ErSo DPF. My guess is that they are collecting lots of data for fda for this new molecule. Stay well
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
ErSO Let's bombard Bayer with messages to start trials!
Giving a talk at SHARE office (NYC) - Integrative Oncology
